Anticancer drugs
Adagrasib (Everest)
Original price was: £512.00.£461.00Current price is: £461.00.Adagrasib (Brand name: Krazati) is an FDA-approved KRAS G12C targeted therapy indicated for the treatment of advanced non-small cell lung cancer (NSCLC).
It is the second KRAS G12C inhibitor approved following sotorasib and has demonstrated activity in certain patients who developed resistance to previous KRAS-targeted therapies.
MedFind provides overseas sourcing services for Adagrasib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process, along with authenticity assurance and fast shipment availability.
Alectinib (Anshengsha, Everest)
Original price was: £370.00.£194.00Current price is: £194.00.Alectinib produced by Everest (also translated as Ailetinib or Alectinib; brand name: Alecensa/Anshengsha) is a second-generation ALK inhibitor developed by the U.S. pharmaceutical company Roche.
Alectinib was first approved by the U.S. FDA in December 2015 for the treatment of non-small cell lung cancer (NSCLC) patients who had developed resistance to crizotinib. In November 2017, it was further approved for first-line treatment of advanced ALK-positive NSCLC.
Avatrombopag (Everest)
Original price was: £208.00.£182.00Current price is: £182.00.Avatrombopag (Avatrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate bone marrow platelet production and help reduce the risk of bleeding caused by thrombocytopenia.
MedFind provides overseas sourcing services for Avatrombopag through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Supports platelet recovery for patients with low platelet counts before surgery and those with chronic immune thrombocytopenia (ITP), with product authenticity assurance, fast shipment availability, and professional consultation support.
Cabozantinib (Everest)
Original price was: £299.00.£245.00Current price is: £245.00.Cabozantinib manufactured by Everest Pharma is a multi-target broad-spectrum anticancer therapy that has demonstrated promising clinical efficacy across a wide range of solid tumors.
Cabozantinib has shown beneficial treatment effects in:
- Renal cell carcinoma (kidney cancer)
- Thyroid cancer
- Liver cancer
- Soft tissue sarcoma
- Non-small cell lung cancer (NSCLC)
- Prostate cancer
- Breast cancer
- Ovarian cancer
- Colorectal cancer
and several other advanced malignancies.
Cabozantinib is particularly recognized for its strong effectiveness in controlling bone metastases, helping reduce tumor progression and complications associated with metastatic bone disease.
Due to its broad antitumor activity across multiple cancer types, Cabozantinib is often referred to as a “multi-purpose” or “broad-spectrum” targeted therapy among tyrosine kinase inhibitors (TKIs).
Capmatinib (Everest)
Original price was: £512.00.£429.00Current price is: £429.00.Capmatinib (Capmatinib) is a selective MET inhibitor used for the targeted treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping mutations. By inhibiting abnormal activation of the MET signaling pathway, Capmatinib helps effectively suppress tumor cell growth and spread.
Capmaxen by Everest Pharma is a high-quality generic version of Capmatinib, offering patients a more affordable treatment option. MedFind provides overseas sourcing services for Capmatinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Crizotinib (brand name: Xalkori, Sekuri; Incepta).
Original price was: £379.00.£249.00Current price is: £249.00.Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer in the United States. It has demonstrated significant clinical efficacy in patients with tumors characterized by abnormal ALK, ROS1, and MET kinase activity.
MedFind provides access to Crizotinib through verified overseas procurement channels, with guaranteed authenticity, in-stock availability, rapid shipping, full logistics tracking, and privacy-protected handling. Professional guidance is available upon inquiry, including information on indications, clinical efficacy, adverse effects, and medication usage instructions.
Erdafitinib (Everest)
Original price was: £600.00.£499.00Current price is: £499.00.Erdafitinib (Brand name: Balversa) is an oral pan-FGFR tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic urothelial carcinoma carrying FGFR2 or FGFR3 genetic alterations, especially in cases where platinum-based chemotherapy has failed.
MedFind provides overseas sourcing services for Erdafitinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Gilteritinib / Xospata (Everest)
Original price was: £412.00.£396.00Current price is: £396.00.Gilteritinib (Brand name: Xospata) is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations.
It is also being actively studied in multiple clinical trials for additional AML subtypes and combination treatment strategies, including first-line therapy, maintenance therapy, and use in combination with chemotherapy or other targeted therapies.
MedFind provides overseas sourcing services for Gilteritinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Learn more about indications, clinical efficacy, side effects, and medication guidance.
Ibrutinib (also translated as Yilutini; brand name: Yike; Incepta).
Original price was: £399.00.£238.00Current price is: £238.00.Ibrutinib produced by Incepta (generic name: Ibrutinib, also translated as Yilutini; brand names: Imbruvica, Yike) is an oral Bruton’s tyrosine kinase (BTK) inhibitor. It exerts its antitumor effect by inhibiting BTK, which is required for tumor cell proliferation and metastasis.
It is used for the treatment of relapsed mantle cell lymphoma, relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia.
Ibrutinib / Ibrutinib Capsules / Imbruvica (Everest)
Original price was: £300.00.£249.00Current price is: £249.00.Ibrutinib (Brand name: Imbruvica) is an oral BTK inhibitor used for the treatment of relapsed mantle cell lymphoma (MCL), relapsed chronic lymphocytic leukemia (CLL), CLL with 17p deletion, and Waldenström’s macroglobulinemia (WM).
MedFind provides overseas sourcing services for Ibrutinib through regulated international channels, with full logistics tracking and encrypted privacy protection throughout the process.
Larotrectinib / Vitrakvi (Everest)
Price range: £269.00 through £554.00Larotrectinib (Brand name: Vitrakvi) manufactured by Everest Pharma is a targeted therapy used for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions, regardless of where the cancer originated in the body.
Larotrectinib became the first FDA-approved tumor-agnostic targeted therapy based solely on the presence of a specific genetic mutation rather than cancer type or tumor location.
Clinical studies demonstrated efficacy across 17 different adult and pediatric tumor types, highlighting its broad-spectrum anticancer activity in patients with NTRK fusion-positive cancers.
Lorlatinib / Lorbrena (Everest)
Original price was: £409.00.£347.00Current price is: £347.00.Lorlatinib (also known as Lorlatinib; Brand name: Lorbrena) is a third-generation ALK and ROS1 tyrosine kinase inhibitor (TKI) with broad coverage against ALK resistance mutations and strong central nervous system (CNS) penetration.
Lorlatinib demonstrates potent activity against resistance mutations that develop after treatment with crizotinib and second-generation ALK inhibitors, making it an important targeted therapy option for advanced ALK-positive non-small cell lung cancer (NSCLC).
MedFind provides overseas sourcing services for Lorlatinib through regulated international channels, with authenticity assurance, fast shipment availability, full logistics tracking, and encrypted privacy protection throughout the process.